Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Viva Biotech Holdings's pretax income for the
six
months ended in Dec. 2025 was €17.7 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was €38.5 Mil.
Viva Biotech Holdings's pretax margin was 16.30%.
During the past 10 years, Viva Biotech Holdings's highest Pretax Margin was 86.96%. The lowest was -51.11%. And the median was 17.46%.
During the past 10 years, Viva Biotech Holdings's highest Pretax Margin was 86.96%. The lowest was -51.11%. And the median was 17.46%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings Pre-Tax Income Related Terms
Viva Biotech Holdings Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, MRNA: Pre-Tax Income Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €38.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Pre-Tax Income of €38.5 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Pre-Tax Income too high?
Viva Biotech Holdings' current Pre-Tax Income is €38.5 Mil. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Pre-Tax Income compare to VRTX and REGN?
Viva Biotech Holdings' Pre-Tax Income of €38.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Pre-Tax Income is €38.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.14 — trading 80% above its estimated fair value. The current Pre-Tax Income is €38.5 Mil. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Pre-Tax Income is €38.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.14 is trading 80% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Pre-Tax Income: €38.5 Mil
GF Value™: €0.08 vs. price of €0.14 (80% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
